SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
BiologicsMolecular Targeted Therapeutics

PUBLISHER: Fairfield Market Research | PRODUCT CODE: 2122123

Cover Image

PUBLISHER: Fairfield Market Research | PRODUCT CODE: 2122123

Monoclonal Antibodies Market Insights, Competitive Landscape, and Market Forecast - 2033

PUBLISHED:
PAGES: 193 Pages
DELIVERY TIME: 2-5 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF & Excel (Single User License)
USD 4995
Unprintable PDF & Excel (Multi User License upto 5 users)
USD 8495
Printable PDF & Excel (Enterprise License above 5 users)
USD 10600

Add to Cart

Description

Table of Contents

The global monoclonal antibodies market is witnessing strong growth as rising cancer prevalence, increasing adoption of targeted therapies, growing demand for biologic drugs, and advancements in antibody engineering drive market expansion. Monoclonal antibodies are increasingly used across oncology, autoimmune diseases, infectious diseases, and hematological disorders due to their ability to target specific disease-related molecules and pathways. The global monoclonal antibodies market is expected to be valued at US$ 251.30 billion in 2026 and is projected to reach US$ 474.34 billion by 2033, growing at a CAGR of 9.5% between 2026 and 2033.

Market Insights

The market is undergoing significant transformation with advancements in antibody engineering, bispecific antibodies, humanized antibodies, and next-generation biologics. Pharmaceutical and biotechnology companies are investing heavily in research and development to improve antibody specificity, efficacy, safety, and treatment outcomes. The growing use of monoclonal antibodies in cancer immunotherapy and autoimmune disease management is further expanding their clinical applications. Increasing regulatory approvals, development of biosimilars, and improvements in biologics manufacturing are also supporting market accessibility. In addition, strategic collaborations between pharmaceutical companies, biotechnology firms, and research institutions are accelerating the development of innovative antibody-based therapies.

Drivers

The major drivers of the monoclonal antibodies market include the rising burden of cancer and chronic diseases, increasing demand for targeted therapies, advancements in biologics research, and growing adoption of personalized medicine. Monoclonal antibodies provide targeted treatment options with improved therapeutic precision, making them increasingly important in oncology and autoimmune disease management. Growing investment in antibody discovery and engineering technologies is enabling the development of more effective and specialized therapies. The expansion of biologics pipelines and increasing healthcare expenditure are also supporting market growth. Furthermore, the growing availability of biosimilars is improving access to antibody-based treatments while creating new opportunities for manufacturers.

Business Opportunity

The market presents substantial opportunities for pharmaceutical and biotechnology companies developing next-generation monoclonal antibody therapies. Bispecific antibodies, antibody-drug conjugates, and engineered antibodies offer significant potential for product differentiation and treatment innovation. Companies can also capitalize on the expanding biosimilars market by developing cost-effective alternatives to established biologic therapies. Increasing demand for monoclonal antibodies in emerging markets creates additional opportunities for manufacturers to expand their geographic presence. Strategic partnerships, licensing agreements, contract development and manufacturing organizations, and investments in advanced biologics production facilities can further strengthen market positioning. Companies focusing on precision medicine, combination therapies, and novel antibody platforms are well positioned to benefit from long-term market opportunities.

Region Analysis

North America represents a significant market due to advanced healthcare infrastructure, high adoption of biologic therapies, strong pharmaceutical research capabilities, and substantial investment in oncology and immunology. Europe is also witnessing steady growth supported by increasing demand for innovative biologics, expanding clinical research activities, and the growing adoption of biosimilars. East Asia offers considerable opportunities due to expanding biotechnology industries, rising healthcare expenditure, and increasing investments in pharmaceutical research and manufacturing, particularly in China, Japan, and South Korea. South Asia & Oceania are expected to experience continued expansion as healthcare access improves, pharmaceutical manufacturing capabilities increase, and awareness of advanced therapies grows. Latin America and the Middle East & Africa are gradually developing markets, supported by improving healthcare infrastructure, increasing investment in biotechnology, and growing access to advanced therapeutic products.

Companies Covered

  • Roche
  • Johnson & Johnson
  • AbbVie
  • Amgen
  • Bristol Myers Squibb
  • AstraZeneca
  • Merck & Co.
  • Sanofi
  • Novartis
  • Eli Lilly and Company
  • Regeneron Pharmaceuticals
  • BeiGene
  • Daiichi Sankyo
  • Biocon Biologics
  • Samsung Bioepis
  • Genentech (a member of the Roche Group)
  • Halozyme Therapeutics

Market Segmentation

By Antibody Type

  • Human Monoclonal Antibodies
  • Humanized Monoclonal Antibodies
  • Chimeric Monoclonal Antibodies
  • Murine Monoclonal Antibodies
  • Bispecific Monoclonal Antibodies

By Application

  • Oncology
  • Autoimmune & Inflammatory Diseases
  • Infectious Diseases
  • Hematology
  • Others

By End User

  • Hospitals
  • Specialty Clinics
  • Cancer Centers
  • Research Institutes

By Regions

  • North America
  • Europe
  • East Asia
  • South Asia & Oceania
  • Latin America
  • Middle East & Africa
Show more

Table of Contents

1. Executive Summary

  • 1.1. Global Monoclonal Antibodies Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2026
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. COVID-19 Impact Analysis
  • 2.5. Porter's Five Forces Analysis
  • 2.6. Impact of Russia-Ukraine Conflict
  • 2.7. PESTLE Analysis
  • 2.8. Regulatory Analysis
  • 2.9. Price Trend Analysis
    • 2.9.1. Current Prices and Future Projections, 2025-2033
    • 2.9.2. Price Impact Factors

3. Global Monoclonal Antibodies Market Outlook, 2020-2033

  • 3.1. Global Monoclonal Antibodies Market Outlook, by Antibodies Type, Value (US$ Bn), 2020-2033
    • 3.1.1. Human Monoclonal Antibodies
    • 3.1.2. Humanized Monoclonal Antibodies
    • 3.1.3. Chimeric Monoclonal Antibodies
    • 3.1.4. Murine Monoclonal Antibodies
    • 3.1.5. Bispecific Monoclonal Antibodies
  • 3.2. Global Monoclonal Antibodies Market Outlook, by Application, Value (US$ Bn), 2020-2033
    • 3.2.1. Oncology
    • 3.2.2. Autoimmune & Inflammatory Diseases
    • 3.2.3. Infectious Diseases
    • 3.2.4. Hematology
    • 3.2.5. Others
  • 3.3. Global Monoclonal Antibodies Market Outlook, by End User, Value (US$ Bn), 2020-2033
    • 3.3.1. Hospitals
    • 3.3.2. Specialty Clinics
    • 3.3.3. Cancer Centers
    • 3.3.4. Research Institutes
  • 3.4. Global Monoclonal Antibodies Market Outlook, by Region, Value (US$ Bn), 2020-2033
    • 3.4.1. North America
    • 3.4.2. Europe
    • 3.4.3. Asia Pacific
    • 3.4.4. Latin America
    • 3.4.5. Middle East & Africa

4. North America Monoclonal Antibodies Market Outlook, 2020-2033

  • 4.1. North America Monoclonal Antibodies Market Outlook, by Antibodies Type, Value (US$ Bn), 2020-2033
    • 4.1.1. Human Monoclonal Antibodies
    • 4.1.2. Humanized Monoclonal Antibodies
    • 4.1.3. Chimeric Monoclonal Antibodies
    • 4.1.4. Murine Monoclonal Antibodies
    • 4.1.5. Bispecific Monoclonal Antibodies
  • 4.2. North America Monoclonal Antibodies Market Outlook, by Application, Value (US$ Bn), 2020-2033
    • 4.2.1. Oncology
    • 4.2.2. Autoimmune & Inflammatory Diseases
    • 4.2.3. Infectious Diseases
    • 4.2.4. Hematology
    • 4.2.5. Others
  • 4.3. North America Monoclonal Antibodies Market Outlook, by End User, Value (US$ Bn), 2020-2033
    • 4.3.1. Hospitals
    • 4.3.2. Specialty Clinics
    • 4.3.3. Cancer Centers
    • 4.3.4. Research Institutes
  • 4.4. North America Monoclonal Antibodies Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 4.4.1. U.S. Monoclonal Antibodies Market Outlook, by Antibodies Type, 2020-2033
    • 4.4.2. U.S. Monoclonal Antibodies Market Outlook, by Application, 2020-2033
    • 4.4.3. U.S. Monoclonal Antibodies Market Outlook, by End User, 2020-2033
    • 4.4.4. Canada Monoclonal Antibodies Market Outlook, by Antibodies Type, 2020-2033
    • 4.4.5. Canada Monoclonal Antibodies Market Outlook, by Application, 2020-2033
    • 4.4.6. Canada Monoclonal Antibodies Market Outlook, by End User, 2020-2033
  • 4.5. BPS Analysis/Market Attractiveness Analysis

5. Europe Monoclonal Antibodies Market Outlook, 2020-2033

  • 5.1. Europe Monoclonal Antibodies Market Outlook, by Antibodies Type, Value (US$ Bn), 2020-2033
    • 5.1.1. Human Monoclonal Antibodies
    • 5.1.2. Humanized Monoclonal Antibodies
    • 5.1.3. Chimeric Monoclonal Antibodies
    • 5.1.4. Murine Monoclonal Antibodies
    • 5.1.5. Bispecific Monoclonal Antibodies
  • 5.2. Europe Monoclonal Antibodies Market Outlook, by Application, Value (US$ Bn), 2020-2033
    • 5.2.1. Oncology
    • 5.2.2. Autoimmune & Inflammatory Diseases
    • 5.2.3. Infectious Diseases
    • 5.2.4. Hematology
    • 5.2.5. Others
  • 5.3. Europe Monoclonal Antibodies Market Outlook, by End User, Value (US$ Bn), 2020-2033
    • 5.3.1. Hospitals
    • 5.3.2. Specialty Clinics
    • 5.3.3. Cancer Centers
    • 5.3.4. Research Institutes
  • 5.4. Europe Monoclonal Antibodies Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 5.4.1. Germany Monoclonal Antibodies Market Outlook, by Antibodies Type, 2020-2033
    • 5.4.2. Germany Monoclonal Antibodies Market Outlook, by Application, 2020-2033
    • 5.4.3. Germany Monoclonal Antibodies Market Outlook, by End User, 2020-2033
    • 5.4.4. Italy Monoclonal Antibodies Market Outlook, by Antibodies Type, 2020-2033
    • 5.4.5. Italy Monoclonal Antibodies Market Outlook, by Application, 2020-2033
    • 5.4.6. Italy Monoclonal Antibodies Market Outlook, by End User, 2020-2033
    • 5.4.7. France Monoclonal Antibodies Market Outlook, by Antibodies Type, 2020-2033
    • 5.4.8. France Monoclonal Antibodies Market Outlook, by Application, 2020-2033
    • 5.4.9. France Monoclonal Antibodies Market Outlook, by End User, 2020-2033
    • 5.4.10. U.K. Monoclonal Antibodies Market Outlook, by Antibodies Type, 2020-2033
    • 5.4.11. U.K. Monoclonal Antibodies Market Outlook, by Application, 2020-2033
    • 5.4.12. U.K. Monoclonal Antibodies Market Outlook, by End User, 2020-2033
    • 5.4.13. Spain Monoclonal Antibodies Market Outlook, by Antibodies Type, 2020-2033
    • 5.4.14. Spain Monoclonal Antibodies Market Outlook, by Application, 2020-2033
    • 5.4.15. Spain Monoclonal Antibodies Market Outlook, by End User, 2020-2033
    • 5.4.16. Russia Monoclonal Antibodies Market Outlook, by Antibodies Type, 2020-2033
    • 5.4.17. Russia Monoclonal Antibodies Market Outlook, by Application, 2020-2033
    • 5.4.18. Russia Monoclonal Antibodies Market Outlook, by End User, 2020-2033
    • 5.4.19. Rest of Europe Monoclonal Antibodies Market Outlook, by Antibodies Type, 2020-2033
    • 5.4.20. Rest of Europe Monoclonal Antibodies Market Outlook, by Application, 2020-2033
    • 5.4.21. Rest of Europe Monoclonal Antibodies Market Outlook, by End User, 2020-2033
  • 5.5. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Monoclonal Antibodies Market Outlook, 2020-2033

  • 6.1. Asia Pacific Monoclonal Antibodies Market Outlook, by Antibodies Type, Value (US$ Bn), 2020-2033
    • 6.1.1. Human Monoclonal Antibodies
    • 6.1.2. Humanized Monoclonal Antibodies
    • 6.1.3. Chimeric Monoclonal Antibodies
    • 6.1.4. Murine Monoclonal Antibodies
    • 6.1.5. Bispecific Monoclonal Antibodies
  • 6.2. Asia Pacific Monoclonal Antibodies Market Outlook, by Application, Value (US$ Bn), 2020-2033
    • 6.2.1. Oncology
    • 6.2.2. Autoimmune & Inflammatory Diseases
    • 6.2.3. Infectious Diseases
    • 6.2.4. Hematology
    • 6.2.5. Others
  • 6.3. Asia Pacific Monoclonal Antibodies Market Outlook, by End User, Value (US$ Bn), 2020-2033
    • 6.3.1. Hospitals
    • 6.3.2. Specialty Clinics
    • 6.3.3. Cancer Centers
    • 6.3.4. Research Institutes
  • 6.4. Asia Pacific Monoclonal Antibodies Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 6.4.1. China Monoclonal Antibodies Market Outlook, by Antibodies Type, 2020-2033
    • 6.4.2. China Monoclonal Antibodies Market Outlook, by Application, 2020-2033
    • 6.4.3. China Monoclonal Antibodies Market Outlook, by End User, 2020-2033
    • 6.4.4. Japan Monoclonal Antibodies Market Outlook, by Antibodies Type, 2020-2033
    • 6.4.5. Japan Monoclonal Antibodies Market Outlook, by Application, 2020-2033
    • 6.4.6. Japan Monoclonal Antibodies Market Outlook, by End User, 2020-2033
    • 6.4.7. South Korea Monoclonal Antibodies Market Outlook, by Antibodies Type, 2020-2033
    • 6.4.8. South Korea Monoclonal Antibodies Market Outlook, by Application, 2020-2033
    • 6.4.9. South Korea Monoclonal Antibodies Market Outlook, by End User, 2020-2033
    • 6.4.10. India Monoclonal Antibodies Market Outlook, by Antibodies Type, 2020-2033
    • 6.4.11. India Monoclonal Antibodies Market Outlook, by Application, 2020-2033
    • 6.4.12. India Monoclonal Antibodies Market Outlook, by End User, 2020-2033
    • 6.4.13. Southeast Asia Monoclonal Antibodies Market Outlook, by Antibodies Type, 2020-2033
    • 6.4.14. Southeast Asia Monoclonal Antibodies Market Outlook, by Application, 2020-2033
    • 6.4.15. Southeast Asia Monoclonal Antibodies Market Outlook, by End User, 2020-2033
    • 6.4.16. Rest of SAO Monoclonal Antibodies Market Outlook, by Antibodies Type, 2020-2033
    • 6.4.17. Rest of SAO Monoclonal Antibodies Market Outlook, by Application, 2020-2033
    • 6.4.18. Rest of SAO Monoclonal Antibodies Market Outlook, by End User, 2020-2033
  • 6.5. BPS Analysis/Market Attractiveness Analysis

7. Latin America Monoclonal Antibodies Market Outlook, 2020-2033

  • 7.1. Latin America Monoclonal Antibodies Market Outlook, by Antibodies Type, Value (US$ Bn), 2020-2033
    • 7.1.1. Human Monoclonal Antibodies
    • 7.1.2. Humanized Monoclonal Antibodies
    • 7.1.3. Chimeric Monoclonal Antibodies
    • 7.1.4. Murine Monoclonal Antibodies
    • 7.1.5. Bispecific Monoclonal Antibodies
  • 7.2. Latin America Monoclonal Antibodies Market Outlook, by Application, Value (US$ Bn), 2020-2033
    • 7.2.1. Oncology
    • 7.2.2. Autoimmune & Inflammatory Diseases
    • 7.2.3. Infectious Diseases
    • 7.2.4. Hematology
    • 7.2.5. Others
  • 7.3. Latin America Monoclonal Antibodies Market Outlook, by End User, Value (US$ Bn), 2020-2033
    • 7.3.1. Hospitals
    • 7.3.2. Specialty Clinics
    • 7.3.3. Cancer Centers
    • 7.3.4. Research Institutes
  • 7.4. Latin America Monoclonal Antibodies Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 7.4.1. Brazil Monoclonal Antibodies Market Outlook, by Antibodies Type, 2020-2033
    • 7.4.2. Brazil Monoclonal Antibodies Market Outlook, by Application, 2020-2033
    • 7.4.3. Brazil Monoclonal Antibodies Market Outlook, by End User, 2020-2033
    • 7.4.4. Mexico Monoclonal Antibodies Market Outlook, by Antibodies Type, 2020-2033
    • 7.4.5. Mexico Monoclonal Antibodies Market Outlook, by Application, 2020-2033
    • 7.4.6. Mexico Monoclonal Antibodies Market Outlook, by End User, 2020-2033
    • 7.4.7. Argentina Monoclonal Antibodies Market Outlook, by Antibodies Type, 2020-2033
    • 7.4.8. Argentina Monoclonal Antibodies Market Outlook, by Application, 2020-2033
    • 7.4.9. Argentina Monoclonal Antibodies Market Outlook, by End User, 2020-2033
    • 7.4.10. Rest of LATAM Monoclonal Antibodies Market Outlook, by Antibodies Type, 2020-2033
    • 7.4.11. Rest of LATAM Monoclonal Antibodies Market Outlook, by Application, 2020-2033
    • 7.4.12. Rest of LATAM Monoclonal Antibodies Market Outlook, by End User, 2020-2033
  • 7.5. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Monoclonal Antibodies Market Outlook, 2020-2033

  • 8.1. Middle East & Africa Monoclonal Antibodies Market Outlook, by Antibodies Type, Value (US$ Bn), 2020-2033
    • 8.1.1. Human Monoclonal Antibodies
    • 8.1.2. Humanized Monoclonal Antibodies
    • 8.1.3. Chimeric Monoclonal Antibodies
    • 8.1.4. Murine Monoclonal Antibodies
    • 8.1.5. Bispecific Monoclonal Antibodies
  • 8.2. Middle East & Africa Monoclonal Antibodies Market Outlook, by Application, Value (US$ Bn), 2020-2033
    • 8.2.1. Oncology
    • 8.2.2. Autoimmune & Inflammatory Diseases
    • 8.2.3. Infectious Diseases
    • 8.2.4. Hematology
    • 8.2.5. Others
  • 8.3. Middle East & Africa Monoclonal Antibodies Market Outlook, by End User, Value (US$ Bn), 2020-2033
    • 8.3.1. Hospitals
    • 8.3.2. Specialty Clinics
    • 8.3.3. Cancer Centers
    • 8.3.4. Research Institutes
  • 8.4. Middle East & Africa Monoclonal Antibodies Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 8.4.1. GCC Monoclonal Antibodies Market Outlook, by Antibodies Type, 2020-2033
    • 8.4.2. GCC Monoclonal Antibodies Market Outlook, by Application, 2020-2033
    • 8.4.3. GCC Monoclonal Antibodies Market Outlook, by End User, 2020-2033
    • 8.4.4. South Africa Monoclonal Antibodies Market Outlook, by Antibodies Type, 2020-2033
    • 8.4.5. South Africa Monoclonal Antibodies Market Outlook, by Application, 2020-2033
    • 8.4.6. South Africa Monoclonal Antibodies Market Outlook, by End User, 2020-2033
    • 8.4.7. Egypt Monoclonal Antibodies Market Outlook, by Antibodies Type, 2020-2033
    • 8.4.8. Egypt Monoclonal Antibodies Market Outlook, by Application, 2020-2033
    • 8.4.9. Egypt Monoclonal Antibodies Market Outlook, by End User, 2020-2033
    • 8.4.10. Nigeria Monoclonal Antibodies Market Outlook, by Antibodies Type, 2020-2033
    • 8.4.11. Nigeria Monoclonal Antibodies Market Outlook, by Application, 2020-2033
    • 8.4.12. Nigeria Monoclonal Antibodies Market Outlook, by End User, 2020-2033
    • 8.4.13. Rest of Middle East Monoclonal Antibodies Market Outlook, by Antibodies Type, 2020-2033
    • 8.4.14. Rest of Middle East Monoclonal Antibodies Market Outlook, by Application, 2020-2033
    • 8.4.15. Rest of Middle East Monoclonal Antibodies Market Outlook, by End User, 2020-2033
  • 8.5. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. Company Vs Segment Heatmap
  • 9.2. Company Market Share Analysis, 2025
  • 9.3. Competitive Dashboard
  • 9.4. Company Profiles
    • 9.4.1. Roche
      • 9.4.1.1. Company Overview
      • 9.4.1.2. Product Portfolio
      • 9.4.1.3. Financial Overview
      • 9.4.1.4. Business Strategies and Developments
    • 9.4.2. Johnson & Johnson
    • 9.4.3. AbbVie
    • 9.4.4. Amgen
    • 9.4.5. Bristol Myers Squibb
    • 9.4.6. AstraZeneca
    • 9.4.7. Merck & Co.
    • 9.4.8. Sanofi
    • 9.4.9. Novartis
    • 9.4.10. Eli Lilly and Company

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!